Abstract: A use of THP (Pirarubicin) in preparation of a medicament for enhancing antitumor efficacy of V?9V?2 T cells is provided. It is discovered that a surface marker MIC A/B of tumor cells treated with THP is significantly enhanced, and THP-induced tumor cells enable V?9V?2 T cells to highly express NKG2D. An NKG2D/MIC A/B pathway is a classical pathway through which V?9V?2 T cells exert a killing effect. THP significantly enhances an ability of V?9V?2 T cells to kill hepatocellular carcinoma cells through regulating the NKG2D/MIC A/B pathway, and provides a new therapeutic solution for TACE (transcatheter arterial chemoembolization) surgical treatment of clinical cancer patients.

Abstract: Provided herein are compounds, pharmaceutical compositions, and methods for treating a SARS-CoV-2 infection.

Abstract: The present disclosure provides a re-identification method, including: acquiring a captured image; determining, according to the captured image, coordinate information and multiple local blocks of the pedestrian to be identified; inputting the coordinate information and the multiple local blocks into a pedestrian re-identification model to obtain a corresponding global pedestrian feature and multiple local pedestrian features; obtaining a global pedestrian re-identification result according to the global pedestrian feature and global pedestrian features of multiple identified pedestrians pre-stored in a database; obtaining a local pedestrian re-identification result according to the local pedestrian features and local pedestrian features of multiple identified pedestrians pre-stored in the database; and determining an identified pedestrian corresponding to the pedestrian to be identified according to the global pedestrian re-identification result and the local pedestrian re-identification result.

Abstract: Described herein are PHD inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of anemia.

Abstract: Provided for compounds and methods for modulating or inhibiting CBL-B.

Abstract: Provided herein are anti-apoptotic BCL-2 family protein degraders, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a disorder, disease, or condition mediated by an anti-apoptotic BCL-2 family protein.

Abstract: The invention relates to an indole derivative shown in general formula (I-1) and its use in preparing drugs for preventing and/or treating indications of S1P receptor related disorders. The indole derivative of the invention is replaced by R1, R2, R5, and R6 at different sites respectively, and the obtained modified indole derivative has excellent biological activity and is an ideal S1P receptor regulator with high efficiency. Compounds of general formula (I-1) can be used to treat and/or prevent Crohn's disease, ulcerative colitis, psoriasis, rheumatoid arthritis, multiple sclerosis, atopic dermatitis, eosinophilic esophagitis, alopecia areata, primary cholangitis, pyoderma gangrenosum, graft-versus-host disease, amyotrophic lateral sclerosis, systemic lupus erythematosus, type I diabetes arteriosclerosis, atherosclerosis, scleroderma, autoimmune hepatitis, acne, microbial infection, viral infection, and other autoimmune and inflammatory diseases.

Abstract: Described herein are KIF18A inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with KIF18A.

Abstract: A class of substituted pyrrolo[3,4-c]pyrazoles for treating gastric acid-related diseases is described as represented by the following formula (I):

Abstract: A novel type of pyrrolopyrazole derivatives shown in general formula (I), a preparation method thereof and application thereof or a pharmaceutical composition containing same as a therapeutic agent, particularly as a gastric acid secretion inhibitor and a potassium-competitive acid blocker (P-CABs) in biomedicine.

Abstract: Disclosed are a pyrrolopyrazole derivative, a preparation method therefor, and the medical use thereof. In particular, disclosed are a novel class of pyrrolopyrazole derivatives represented by general formula (I), a preparation method therefor, and the use of the pyrrolopyrazole derivatives or pharmaceutical compositions containing the pyrrolopyrazole derivatives in biomedicine as therapeutic agents, particularly as gastric acid secretion inhibitors and potassium ion competitive acid blochers (P-CABs). The definitions of various substituent (R1, R2, R3, R4) and the group (X) in general formula (I) are the same as the definitions in the description.

Abstract: A method for extracting and separating salt alkali from saline alkali soil and soil improvement is disclosed. A foundation pit, square convex edge and cylindrical partition are arranged on a saline alkali land. Nitric or phosphoric acid solution is added to obtain a saline alkali pool. A trench is set around, and/or, a cylinder is set in the center of saline alkali pool. The evaporating material is prepared from vermiculite, laid on plastic wrapping material, and/or added into the cylinder. The salt alkali is precipitated and enriched through natural evaporation. The evaporating material enriched with salt alkali is taken out to be dissolved, separated and washed to obtain saline alkali solution and vermiculite or evaporating material. The vermiculite material is returned for reuse, and the above process is repeated. Alkali solution and intercalation agent are added into saline alkali solution to react and crystallize to obtain functional materials.

Abstract: Described herein are DGKalpha inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with DGKalpha.

Abstract: Provided herein are FAK degraders, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a disorder, disease, or condition mediated by an FAK.

Abstract: Providing compounds of Formula (A) or pharmaceutically acceptable salts, solvate, stereoisomer, or isotopic variant thereof useful as PKMYT1 inhibitors, pharmaceutical compositions comprising the same, and use thereof in the manufacture of medicaments for treating PKMYT1-associated diseases or conditions such as advanced solid tumor, and etc.

Abstract: Described herein are PKMYT1 (Myt1) inhibitors and pharmaceutical compositions comprising said inhibitors. The compounds and compositions are useful for the treatment of a disease or disorder associated with PKMYT1.

Abstract: Described herein are PKMYT1 (Myt1) inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with PKMYT1.

Abstract: The present invention discloses a pyrimidine heterocyclic compound, and a preparation method and medical use thereof. Specifically, the present invention discloses a pyrimidine heterocyclic compound with a structure shown in Formula (A) or a pharmaceutically acceptable salt thereof (groups are each defined in the specification), a pharmaceutical composition comprising the compound, and use of the compound in treatment of cell proliferative diseases (such as cancers).

Abstract: Described herein are PKMYT1 (Myt1) inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with PKMYT1.

Abstract: Described herein are PKMYT1 (Myt1) inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with PKMYT1.